Tirzepatide and obstructive sleep apnea

Why weight and sleep apnea are tied together

In obstructive sleep apnea (OSA), the upper airway repeatedly narrows or closes during sleep, cutting airflow until a brief awakening reopens it. The National Heart, Lung, and Blood Institute lists obesity as a leading risk factor, alongside large tonsils and hormone changes that can narrow the airway.

Untreated OSA does more than cause snoring and daytime sleepiness. NHLBI links it to stroke and heart attack, and to problems with concentration, memory and decision-making. That is why weight loss, when it is significant enough, can change the course of the condition, not just the number on the scale.

What the trials found

The approval was based on two randomized, placebo-controlled trials in adults with obesity and moderate to severe OSA who did not have type 2 diabetes. One enrolled people who could not or would not use positive airway pressure (PAP); the other enrolled people already using it. Participants took the highest tolerated dose of tirzepatide, 10 or 15 mg weekly, or placebo for 52 weeks.

The main measure was the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing episodes per hour of sleep.

• Without PAP (234 people): AHI fell by about 25 events per hour on tirzepatide versus about 5 on placebo; 42% reached remission or mild, symptom-free OSA versus 16% on placebo.
• With PAP (235 people): AHI fell by about 29 events per hour versus about 6 on placebo; 50% reached remission or mild, symptom-free OSA versus 14%.
• People on tirzepatide also lost significantly more weight, and the FDA notes the AHI improvement is likely related to that weight loss.

Who the approval covers, and who it does not

The indication is specific: moderate to severe OSA in adults with obesity. It does not cover mild OSA, people without obesity or central sleep apnea, which has different causes. It also assumes a proper diagnosis, which usually means a home or in-lab sleep study.

The trials did not include enough people aged 65 or older to say whether results differ with age. They also tested branded tirzepatide. Compounded tirzepatide is not FDA-approved, has not been reviewed by the FDA for safety, effectiveness or quality and has no sleep apnea data.

Tirzepatide and CPAP

The FDA describes PAP as the standard of care for moderate to severe OSA, and the approval does not say tirzepatide replaces it. One of the two trials was done in people who kept using PAP, and they benefited too.

Do not stop CPAP on your own because you have lost weight or feel better. Benefits build gradually over months, and whether you still need PAP is best decided with your sleep physician, often with a repeat sleep study.

Safety and side effects

Common side effects in the OSA trials matched those seen with tirzepatide for weight loss: nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, burping, reflux and hair loss.

Tirzepatide carries a boxed warning about thyroid C-cell tumors in rats; whether it causes them in people is unknown. It is not used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Other warnings include pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration and a risk of inhaling stomach contents under anesthesia or deep sedation. It can reduce the reliability of birth control pills and should not be used in pregnancy.

Sleep apnea is easy to miss

Many adults with OSA do not know they have it. Loud snoring, gasping or choking at night, a partner noticing pauses in breathing, morning headaches, waking unrefreshed and dozing off during the day are common clues. In midlife women, symptoms can look like insomnia or fatigue and may be mistaken for menopause.

If any of these sound familiar, ask about testing before or alongside weight treatment. Diagnosing OSA matters for your heart, your energy and your safety on the road, whatever medicine you end up using.

How HealifyMD fits in

Your HealifyMD clinician will ask about snoring, witnessed pauses, daytime sleepiness and blood pressure, and will point you toward a sleep study if OSA has not been diagnosed. If you have diagnosed moderate to severe OSA and obesity, FDA-approved Zepbound is the option tested for this use; HealifyMD's weight loss membership supports people on branded GLP-1s from $75/month.

If your clinician decides compounded tirzepatide is appropriate for weight management, it is from $399/month, or $750 for 2 months ($375/month), confirmed at the eligibility review. We will not present it as a sleep apnea treatment, and your sleep care should continue with your sleep physician.